The Wall Street Journal
A one-time screening for prostate cancer could prevent further,
unnecessary screenings for most men, according to a study in the journal
Cancer. Researchers compared levels of prostate-specific antigen (PSA),
the key biomarker for prostate cancer, among more than 86,000 men ages
55 to 74. About half the subjects came from the Netherlands, Sweden and
Finland, where they were screened routinely as part of a medical trial.
The other half came from Ireland, where most men aren't screened for
prostate cancer. Based on the differences in prostate-cancer deaths
between the two groups over nine years, the researchers concluded that
routine screening provided little benefit for men with PSA levels below
two nanograms per milliliter of blood, which amounted to two-thirds of
the participants. In order to prevent one death from prostate cancer
among these men, nearly 25,000 of them would have to be regularly
screened. Routine screening was the most effective for the 15% of men
who had PSA levels above four nanograms per milliliter: Fewer than 500
of them would need to be regularly screened to avoid one prostate-cancer
death. A study in the British Medical Journal, published immediately
after the Cancer report, came to a similar conclusion using a different
methodology... Read More